NAD+ IV Therapy vs NMN Supplements: What a Neurologist Recommends

By Dr. Charles Kamen, MD — Board-Certified Neurologist, LiveWell21, Las Vegas, NV
Albert Einstein College of Medicine (MD, 2011) | Yale-New Haven Hospital Internship (2011–2012) | Loma Linda University Neurology Residency (2015–2018) | ABPN Board Certified

One of the most common questions I hear from patients at my Las Vegas practice is some version of: "I already take NMN — do I really need the IV?" It is an excellent question, and it deserves a more thorough answer than the supplement industry or the IV wellness industry typically provides. Both sides have financial incentives to tell you their approach is the right one. I have no stake in selling you supplements. I prescribe what the pharmacology supports for each patient's situation.

This post is my clinical breakdown of the differences between NAD+ IV therapy and oral NMN (nicotinamide mononucleotide) supplementation — what the research actually demonstrates about bioavailability, when each approach is appropriate, and how I combine them in practice at LiveWell21.

First: Understanding the Conversion Pathway

NAD+ itself is a large molecule — too large to survive oral ingestion intact. When you swallow a capsule labeled "NAD+," it is degraded in your gastrointestinal tract before it reaches your bloodstream. This is not controversial; it is basic pharmacokinetics.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — smaller molecules that can survive digestion and be converted into NAD+ by your cells through enzymatic pathways. NMN is converted to NAD+ by the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase). NR is first phosphorylated to NMN by nicotinamide riboside kinases (NRK1/NRK2), then converted to NAD+ through the same NMNAT pathway.¹

The critical point: these conversion steps are rate-limited. Your body can only convert NMN to NAD+ at a certain speed, determined by enzyme availability, tissue-specific expression, and individual genetic variation. No matter how much NMN you take orally, there is a ceiling on how fast and how much NAD+ your cells can produce from it.

IV NAD+ bypasses this entire conversion pathway. The coenzyme enters your bloodstream in its active form, at concentrations determined by the dose administered — not by how efficiently your gut absorbs it or your enzymes convert it.

Bioavailability: The Numbers Matter

A 2022 study published in the Journal of the International Society of Sports Nutrition examined blood NAD+ levels following oral NMN supplementation at 250 mg/day for 12 weeks. Participants showed a meaningful increase in whole-blood NAD+ — approximately 38% above baseline — confirming that oral NMN does raise systemic NAD+ levels in humans.²

That finding is important and I do not dismiss it. Oral NMN works. But context matters. A single IV NAD+ infusion at therapeutic doses (250–500 mg) achieves plasma NAD+ concentrations that are substantially higher — and achieved within hours rather than weeks. The clinical pharmacology literature consistently demonstrates that IV administration achieves 100% bioavailability by definition, since the molecule enters the bloodstream directly. Oral bioavailability of NMN is estimated at roughly 20–30% depending on the formulation, individual gut health, and microbiome composition.³

This is not an abstract distinction. For patients with acutely depleted NAD+ — whether from chronic illness, post-COVID fatigue, addiction recovery, or significant metabolic stress — the difference between a gradual 38% elevation over 12 weeks and a rapid repletion within hours is clinically meaningful.

When Oral NMN Makes Sense

I prescribe oral NMN or NR to patients regularly. It is not an inferior option — it is a different tool for a different clinical scenario. Here is when I recommend oral precursors:

• Daily maintenance between IV sessions. After we achieve target NAD+ levels through IV loading, oral NMN at 500–1000 mg/day helps sustain those levels between infusions. This is the most common use case in my Henderson and Summerlin patients who are on a longevity-focused protocol.
• Generally healthy adults under 50 who are interested in proactive cellular support but do not have symptoms suggesting acute NAD+ depletion. For someone in their 30s or early 40s with good metabolic health, daily oral NMN is a reasonable starting point.
• Cost-conscious patients who want to begin NAD+ support but are not ready for the investment of IV therapy. Good quality NMN supplements cost $40–80/month. IV NAD+ sessions are substantially more. I would rather a patient take NMN consistently than do nothing because IV therapy is outside their budget.
• Patients who respond well to oral supplementation. Some patients report noticeable improvements in energy and mental clarity from oral NMN alone. If the subjective response is strong and consistent, and the clinical picture does not suggest acute depletion, oral supplementation may be sufficient.

When IV NAD+ Is the Better Choice

IV NAD+ becomes the appropriate first-line approach when the clinical situation demands rapid repletion or when oral routes are insufficient:

• Significant cognitive fog or fatigue not responding to conventional treatment. Many Las Vegas metro patients come to me after trying oral supplements without adequate relief. When the symptom burden is high, the gradual elevation from oral NMN is often not fast enough.
• Post-COVID syndrome. SARS-CoV-2 has been demonstrated to deplete NAD+ through hyperactivation of CD38, an NAD+-consuming enzyme. Patients with persistent post-COVID fatigue often have a depth of NAD+ depletion that oral precursors cannot address quickly enough.⁴
• Addiction recovery. Chronic alcohol and opioid use depletes NAD+ stores severely. During the critical early recovery window, rapid NAD+ restoration through IV infusion can meaningfully reduce withdrawal severity and cravings. The timeline of oral supplementation — weeks to achieve modest elevation — does not match the acute clinical need.
• GI absorption issues. Patients with inflammatory bowel conditions, gastric bypass history, SIBO, or other conditions affecting gut absorption may not convert oral NMN efficiently. IV delivery eliminates this variable entirely.
• Patients over 60 with metabolic decline. The enzymes responsible for converting NMN to NAD+ (particularly NMNAT) may themselves be less active in older adults. IV delivery bypasses the enzymatic bottleneck.
• Neurodegenerative disease risk management. For patients with a family history of Alzheimer's or Parkinson's disease who are pursuing aggressive neuroprotective strategies, the higher and more reliable NAD+ levels achieved through IV therapy are part of a comprehensive approach alongside peptide therapy and hormone optimization.

The Combination Protocol: What I Actually Prescribe

In practice, most of my patients end up using both. The protocol I have found most effective over several years of clinical experience is:

Phase 1 — Loading (weeks 1–2): Two to four IV NAD+ infusions over seven to fourteen days, depending on the severity of depletion and patient tolerance. This rapidly restores cellular NAD+ to therapeutic levels.

Phase 2 — Maintenance: Monthly or quarterly IV NAD+ infusions combined with daily oral NMN (typically 500–1000 mg) between sessions. The IV sessions provide periodic high-concentration repletion while the oral precursor maintains baseline elevation.

Phase 3 — Monitoring: I track subjective markers (energy, cognitive clarity, sleep quality) and objective markers (metabolic panel, inflammatory markers) at regular intervals to confirm the protocol is producing measurable results. If a patient is doing well on oral NMN alone after the loading phase, I am comfortable extending or eliminating IV sessions. I adjust based on data, not a fixed schedule.

What About Quality and Regulation?

One issue that rarely gets enough attention: the oral NMN supplement market is poorly regulated. A 2023 analysis by the Clean Label Project found that many NMN products contained significantly less NMN than advertised, and some contained concerning levels of heavy metals. The FDA's 2023 decision to classify NMN as an investigational new drug (later partially reversed) added further confusion about legal availability and quality standards.⁵

If you are taking oral NMN, source it from companies that provide third-party certificates of analysis (CoA) with batch-specific testing. I can recommend specific brands that meet these standards during your consultation at LiveWell21.

IV NAD+ used in clinical settings is compounded by licensed pharmacies under strict quality controls — a significant advantage in terms of purity and dosing accuracy.

The Honest Bottom Line

There is no single correct answer to "NAD+ IV or NMN supplements?" The right approach depends on your age, your current NAD+ status (which we can infer from symptoms and metabolic markers), your GI health, your clinical goals, and your budget.

What I can tell you is this: both approaches are supported by real science. NMN supplementation is not a scam, and IV NAD+ is not just an expensive version of the same thing. They have different pharmacokinetics, different appropriate use cases, and — in my clinical experience — they work best in combination.

If you are in the Las Vegas area — Henderson, Summerlin, or anywhere in the metro — and want a proper clinical evaluation of which approach (or combination) is right for you, I would be happy to have that conversation.

Book a Consultation at LiveWell21

Explore our related services:
NAD+ IV Therapy for Brain Health | NAD+ IV Therapy Service Page | IV Therapy vs. Oral Supplements | Peptide Therapy | Hormone Optimization | Advanced Diagnostics

References

1. Ratajczak J, et al. "NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells." Nature Communications. 2016;7:13103.
2. Yi L, et al. "The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." GeroScience. 2023;45(1):29-43.
3. Mills KF, et al. "Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice." Cell Metabolism. 2016;24(6):795-806.
4. Heer CD, et al. "Coronavirus infection and PARP expression dysregulate the NAD metabolome: an actionable component of innate immunity." Journal of Biological Chemistry. 2020;295(52):17986-17996.
5. Pencina KM, et al. "MIB-626, an oral formulation of a microcrystalline unique polymorph of beta-nicotinamide mononucleotide, increases circulating NMN and NAD in a randomized clinical trial." npj Aging. 2023;9:25.

This content is for educational purposes and does not constitute medical advice. Consult a qualified physician before beginning any supplementation or IV therapy program. Statements about NAD+ IV therapy and NMN supplementation have not been evaluated by the FDA for disease prevention or treatment.